SCHEMBL43660

SCHEMBL43660

CNC(C(=O)O)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716843 1.00 SMN1; SMN2 (0.41)
SCHEMBL161931 1.00
SCHEMBL43661 1.00
Hydrochloric Acid SCHEMBL3947878 0.97 SMN1; SMN2 (0.39)
Hydrochloric Acid SCHEMBL6780690 0.97 SMN1; SMN2 (0.39)
Hydrochloric Acid SCHEMBL3947884 0.97 SMN1; SMN2 (0.39)
Valine SCHEMBL28845417 0.86 SLC7A5 (0.65)
Trifluoroacetic Acid SCHEMBL30405351 0.86 MMP1 (0.36)
SCHEMBL5490834 0.83 TP53 (0.36)
SCHEMBL5490842 0.83 TP53 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9123 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083866-A1 COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2026-03-26 US claimed
US-20260035408-A1 WKYMVm peptide analogues having six residues and uses thereof RESEARCH & BUSINESS FOUND SUNGKYUNKWAN UNIV (KR) 2026-02-05 US claimed
EP-4658676-A2 ANTI-CDH17 ANTIBODIES AND USE OF THE SAME Bighat Biosciences, Inc. (US) 2025-12-10 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4635516-A2 ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES Pfizer Inc. (US) 2025-10-22 EP claimed
WO-2025199636-A1 TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF MCMASTER UNIVERSITY (CA) 2025-10-02 WO claimed
US-20250268982-A1 COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES REGAIN THERAPEUTICS SWEDEN AB (SE) 2025-08-28 US claimed
US-20250161408-A1 PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2025-05-22 US claimed
US-20250111889-A1 DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES UNIVERSITY OF WASHINGTON 2025-04-03 US claimed
US-4997648-A Bactericide, antiinflammatory, immunosuppressive BRITISH TECHNOLOGY GROUP LIMITED (GB) 1991-03-05 US claimed
EP-0378604-A1 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES. ERBA CARLO SPA (IT) 1990-07-25 EP claimed
EP-0352092-A2 Novel antibiotics R106 TAKARA SHUZO CO. LTD. (JP) 1990-01-24 EP claimed
WO-1989010926-A1 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES FARMITALIA CARLO ERBA S.R.L. (IT) 1989-11-16 WO claimed
EP-0300784-A2 Peptides BTG INTERNATIONAL LIMITED (GB) 1989-01-25 EP claimed
EP-0300785-A2 Cyclosporins BTG INTERNATIONAL LIMITED (GB) 1989-01-25 EP claimed
US-4522812-A Novel physiologically active substance K-4, a process for preparation thereof and a pharmaceutical composition containing the same KYOWA HAKKO KOGYO CO., LTD. (JP) 1985-06-11 US claimed
US-4336249-A MYCOPLANECIN PRODUCT CULTIVATED FORM ACTINOPLANES SANKYO COMPANY LIMITED (JP) 1982-06-22 US claimed
US-4118482-A Process for treating neoplastic disease with azetomicins THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1978-10-03 US claimed
US-4053460-A ACTINOMYCIN ANTIBIOTIC ANALOGUES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1977-10-11 US claimed